Positron emission tomography with 18fluorodeoxyglucose in radiation treatment planning for non-small cell lung cancer: A systematic review

Journal of Thoracic Oncology

Volumn 6, Issue 1, 2011, Pages 86-97

  Ung, Yee C ^a   Bezjak, Andrea ^b   Coakley, Nadia ^c   Evans, William K ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c MCMASTER UNIVERSITY   (Canada)

Author keywords

Non small cell lung cancer (NSCLC); Positron emission tomography (PET); Radiation treatment planning; Systematic review

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC TEST ACCURACY STUDY; DISTANT METASTASIS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING; TUMOR VOLUME;

EID: 78651074411     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181fc7687     Document Type: Review

References (63)

1. Canadian Cancer Society, National Cancer Institute of Canada. Canadian Cancer Statistics 2006 [internet]. Toronto, Canada: National Cancer Institute of Canada, 2006. Available at: http://www.cancer.ca/ccs/internet/ standard/0,3182,3543-14279-371283-langId-en,00.html. Accessed September 6, 2006.
2. Tyldesley S, Boyd C, Schulze K, et al. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach. Int J Radiat Oncol Biol Phys 2001;49:973-985.
3. International Committee on Radiation Units and Measurements (ICRU). Prescribing, Recording, and Reporting Photon Beam Therapy. Bethesda, MD: International Committee on Radiation Units, 1993.
4. Chan R, He Y, Haque A, et al. Computed tomographic-pathologic correlation of gross tumor volume and clinical target volume in nonsmall cell lung cancer: a pilot experience. Arch Pathol Lab Med 2001;125:1469-1472.
5. Giraud P, Antoine M, Larrouy A, et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000;48:1015-1024.
6. Li WL, Yu JM, Liu GH, et al. [A comparative study on radiology and pathology target volume in non-small-cell lung cancer.] Zhonghua Zhong Liu Za Zhi 2003;25:566-568;[Abstract in English].
7. Wambersie A, DeLuca P, Whitmore G. Prescribing, recording and reporting electron beam therapy; 2 volumes. J Int Comm Radiat Units Meas (ICRU) 2004;4:25-37.
8. Caldwell CB, Mah K, Ung YC, et al. Observer variation in contouring gross tumor volume in patients with poorly defined non-small-cell lung tumors on CT: the impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys 2001;51:923-931.
9. Van de Steen J, Linthout N, de Mey J, et al. Definition of gross tumor volume in lung cancer: inter-observer variability. Radiother Oncol 2002;62:37-49.
10. Ung YC, Maziak DE, Vanderveen JA, et al. 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review. J Natl Cancer Inst 2007;99:1753-1767.
11. Birim O, Kappetein AP, Stijnen T, et al. Meta-analysis of positron emission tomographic and computed tomographic imaging in detecting mediastinal lymph node metastases in nonsmall cell lung cancer. Ann Thorac Surg 2005;79:375-382.
12. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of nonsmall cell lung cancer: a review of the current evidence. Chest 2003;123(Suppl 1):137S-146S.
13. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small cell lung cancer: a meta-analysis. Ann Intern Med 2003;139:879-892.
14. Fischer BM, Mortensen J, Højgaard L. Positron emission tomography in the diagnosis and staging of lung cancer: a systematic, quantitative review. Lancet Oncol 2001;2:659-666.
15. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999;45:323-329.
16. Yaremko B, Riauka T, Robinson D, et al. Threshold modification for tumour imaging in non-small-cell lung cancer using positron emission tomography. Nucl Med Commun 2005;26:433-440.
17. Ashamalla H, Rafla S, Parikh K, et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. Int J Radiat Oncol Biol Phys 2005; 63:1016-1023.
18. Humm J, Rosenfeld A, Del Guerra A. From PET detectors to PET scanners. Eur J Nucl Med Mol Imaging 2003;30:1574-1597.
19. Browman GP, Levine MN, Mohide EA, et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol 1995;13:502-512.
20. Hebert ME, Lowe VJ, Hoffman JM, et al. Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. Am J Clin Oncol 1996;19:416-421.
21. Kiffer JD, Berlangieri SU, Scott AM, et al. The contribution of 18Ffluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer 1998;19:167-177.
22. Munley MT, Marks LB, Scarfone C, et al. Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer 1999;23:105-114.
23. Nestle U, Walter K, Schmidt S, et al. 18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593-597.
24. Bradley JD, Dehdashti F, Mintun MA, et al. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004;22:3248-3254.
25. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med 2003;44:1911-1917.
26. Gondi V, Bradley K, Mehta M, et al. Impact of hybrid fluorodeoxyglucose positron-emission tomography/computed tomography on radiotherapy planning in esophageal and non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:187-195.
27. Grills IS, Yan D, Black QC, et al. Clinical implications of defining the gross tumor volume with combination of CT and 18FDG-positron emission tomography in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007;67:709-719.
28. Lewandowska A, Windorbska W, Morgas T. Radiation treatment planning using positron emission tomography for patients with non-small cell lung cancer. Nowotwory 2006;56:259-314.
29. Brianzoni E, Rossi G, Ancidei S, et al. Radiotherapy planning: PET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 2005;32:1392-1399.
30. Hong R, Halama J, Bova D, et al. Correlation of PET standard uptake value and CT window-level thresholds for target delineation in CTbased radiation treatment planning. Int J Radiat Oncol Biol Phys 2007;67:720-726.
31. De Ruysscher D, Wanders S, Minken A, et al. Effects of radiotherapy planning with a dedicated combined PET-CT-simulator of patients with non-small cell lung cancer on dose limiting normal tissues and radiation dose-escalation: a planning study. Radiother Oncol 2005;77:5-10.
32. Deniaud-Alexandre E, Touboul E, Lerouge D, et al. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2005;63:1432-1441.
33. Mah K, Caldwell CB, Ung YC, et al. The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys 2002;52:339-350.
34. Giraud P, Grahek D, Montravers F, et al. CT and (18)F-deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys 2001;49:1249-1257.
35. Roman MR, Rossleigh MA, Angelides S, et al. Staging and managing lung tumors using F-18 FDG coincidence detection. Clin Nucl Med 2001;26:383-388.
36. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2004;59:78-86.
37. Schmücking M, Baum RP, Griesinger F, et al. Molecular whole-body cancer staging using positron emission tomography: consequences for therapeutic management and metabolic radiation treatment planning. Recent Res Cancer Res 2003;162:195-202.
38. van Der Wel A, Nijsten S, Hochstenbag M, et al. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: a modeling study. Int J Radiat Oncol Biol Phys 2005;61:649-655.
39. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al. The impact of (18)F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol 2000; 55:317-324.
40. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with nonsmall-cell lung cancer: a prospective study. J Clin Oncol 2001;19:111-118.
41. Roberts KB, Manus MP, Hicks RJ, et al. PET imaging for suspected residual tumour or thoracic recurrence of non-small cell lung cancer after pneumonectomy. Lung Cancer 2005;47:49-57.
42. MacManus MP, Hicks RJ, Ball DL, et al. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment. Cancer 2001;92:886-895.
43. Ceresoli GL, Cattaneo GM, Castellone P, et al. Role of computed tomography and [18F] fluorodeoxyglucose positron emission tomography image fusion in conformal radiotherapy of non-small cell lung cancer: a comparison with standard techniques with and without elective nodal irradiation. Tumori 2007;93:88-96.
44. MacManus M, D'Costa I, Everitt S, et al. Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer. Australas Radiol 2007;51:386-393.
45. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol 2002;62:51-60.
46. Messa C, Ceresoli GL, Rizzo G, et al. Feasibility of [18F]FDG-PET and coregistered CT on clinical target volume definition of advanced nonsmall cell lung cancer. Q J Nucl Med Mol Imaging 2005;49:259-266.
47. Hicks RJ, Kalff V, MacManus MP, et al. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001;42:1596-1604.
48. Ung YC, Sun A, MacRae R, et al. Impact of positron emission tomography (PET) in stage III non-small cell lung cancer (NSCLC): a prospective randomized trial (PET START). J Clin Oncol 2009; 27:[Abstract] 7548.
49. Spratt DE, Diaz R, McElmurray J, et al. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in nonsmall-cell lung cancer. Clin Nucl Med 2010;35:237-243.
50. Feng M, Kong FM, Gross M, et al. Using fluorodeoxyglucose positron emission tomography to assess tumor volume during radiotherapy for non-small-cell lung cancer and its potential impact on adaptive dose escalation and normal tissue sparing. Int J Radiat Oncol Biol Phys 2009;73:1228-1234.
51. Vinod SK, Kumar S, Holloway LC, et al. Dosimetric implications of the addition of 18 flurordeoxyglucose-positron emission tomography in CT-based radiotherapy planning for non-small cell lung cancer. J Med Imaging Radiat Oncol 2010;54:152-160.
52. Hanna GG, McAleese J, Carson KJ, et al. (18)F-FDG PET-CT simulation for non-small-cell lung cancer: effect in patients already staged by PET-CT. Int J Radiat Oncol Biol Phys 2010;77:24-30.
53. Kruser TJ, Bradeley KA, Bentzen SM, et al. The impact of hybrid PET-CT scan on overall oncologic management, with a focus on radiotherapy planning: a prospective, blinded study. Technol Cancer Res Treat 2009;8:149-158.
54. Nestle U, Walter K, Schmidt S, et al. 18F-deoyxglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis. Int J Radiat Oncol Biol Phys 1999;44:593-597.
55. Faria SL, Menard S, Slobodan D, et al. Impact of FDG-PET on radiotherapy volume delineations in non-small cell lung cancer and correlation of imaging stage with pathological findings. Int J Radiat Oncol Biol Phys 2008;70:1035-1385.
56. Wu K, Ung YC, Hornby J, et al. PET CT thresholds for radiotherapy target definition in non-small cell lung cancer: how close are we to the pathological findings. Int J Radiat Oncol Biol Phys 2010;77:699-706.
57. Dahele M, Hwang D, Peressotti C, et al. Developing a methodology for three-dimensional correlation of PET-CT images and whole mount histopathology in non-small cell lung cancer. Curr Oncol 2008;15:62-69.
58. Stroom J, Blaauwgeers H, van Baardwijk A, et al. Feasibility of pathology correlated lung imaging for accurate target definition of lung tumors. Int J Radiat Oncol Biol Phys 2007;69:267-275.
59. van Baardwijk A, Bosmans G, Boersma L, et al. PET CT based auto-contouring in non-small cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes. Int J Radiat Oncol Biol Phys 2007;68:771-778.
60. MacManus MP, Wong K, Hicks RJ, et al. Early mortality after radical radiotherapy for non-small cell lung cancer: comparison of PET staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys 2002;52:351-361.
61. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of detection of unsuspected distant metastases by PET in apparent stage III non-small cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001;50:287-293.
62. Black QC, Grills IS, Kestin LL, et al. Defining a radiotherapy target with positron emission tomography. Int J Radiat Oncol Biol Phys 2004;60: 1272-1282.
63. Biehl KJ, Kong FM, Dehdashti F, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med 2006;47:1808-1812.